US EditionSerena Williams to promote weight-loss drugs with telehealth firm Ro
Serena Williams lost over 31 pounds using GLP-1 medication to manage postpartum weight and improve health, aiming to destigmatize its use through a campaign with telehealth company Ro.
- Serena Williams, the retired tennis champion, announced on August 21, 2025, that she used GLP-1 medication via telehealth company Ro to lose 31 pounds after her second daughter’s birth in August 2023.
- Williams began struggling to regain her healthy weight after giving birth to her first daughter, Olympia, in 2017, and resumed challenges post-2023, leading her to research GLP-1 treatments and start injections in early 2024 after stopping breastfeeding.
- The medication Williams used is part of a class including Ozempic, Wegovy, and Mounjaro, primarily prescribed for diabetes but also effective for weight loss, and she partnered with Ro to promote normalizing these treatments.
- Williams stated, "I feel great," and described feeling physically and mentally lighter, adding that the changes in her body have been "well worth it," while acknowledging she never took shortcuts to lose weight.
- Her public campaign with Ro aims to combat stigma around weight loss drugs and shows that even elite athletes need clinical support, suggesting broader acceptance and access to such treatments may grow.
Insights by Ground AI
Does this summary seem wrong?
54 Articles
54 Articles
Serena Williams turns to GLP-1 drugs: Is it a new era in weight loss?
For decades, fitness influencers and athletes swore by “clean eating” and intense workouts as the ultimate path to weight loss and peak performance. But Serena Williams’s revelation signals a potential cultural shift - are we moving into an era where science, and not sweat alone, drives results?
·India
Read Full Article
Coverage Details
Total News Sources54
Leaning Left17Leaning Right11Center10Last UpdatedBias Distribution45% Left
Bias Distribution
- 45% of the sources lean Left
45% Left
L 45%
C 26%
R 29%
Factuality
To view factuality data please Upgrade to Premium
